Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | CASP2 | P42575 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | F13A1 | P00488 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | THPO | P40225 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10927023 | 0.91 | S1PR2 (0.57) | BLMPMP22LMNACYP3A4NFKB1 | |
| SCHEMBL1479560 | 0.90 | LMNA (0.59) | BLMPMP22LMNACYP3A4NFKB1 | |
| SCHEMBL3447091 | 0.89 | BLM (0.60) | BLMPMP22LMNACYP3A4NFKB1 | |
| Water SCHEMBL10792460 | 0.89 | S1PR2 (0.55) | BLMPMP22LMNACYP3A4NFKB1 | |
| SCHEMBL28846998 | 0.86 | LMNA (0.54) | BLMPMP22LMNACYP3A4NFKB1 | |
| Norspermidine SCHEMBL13386646 | 0.86 | BLM (0.59) | BLMPMP22LMNACYP3A4NFKB1 | |
| Norspermidine SCHEMBL6824685 | 0.86 | BLM (0.59) | BLMPMP22LMNACYP3A4NFKB1 | |
| Spermine SCHEMBL867751 | 0.85 | CA12 (0.68) | BLMPMP22LMNACYP3A4NFKB1 | |
| SCHEMBL243323 | 0.85 | LMNA (0.59) | BLMPMP22LMNACYP3A4NFKB1 | |
| Spermine SCHEMBL2058654 | 0.85 | CA12 (0.68) | BLMPMP22LMNACYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | CULLEN THOMAS GERARD (US) | 2012-05-10 | — | — | US | claimed |
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | claimed |
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | CULLEN THOMAS GERARD (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | disclosed |
| CN-1871246-A | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl[ethyl} phosphonic acid and esters thereof | WYETH CORP (US) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | DERA, ENO1, PPIP5K2 | BLM 4337/4885PMP22 508/4885LMNA 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.